Pharmacogenomics Reporter GenomeWeb News Premium Content Existing subscribers login here. New to Pharmacogenomics Reporter? For a trial subscription click here.

EPO’s Decision to Amend Myriad’s BRCA1 IP
May Create More Uncertainty for Euro Labs

[December 3, 2008]

By Turna Ray

The European Patent Office’s recent decision to partly uphold Myriad Genetics’ BRCA1 patent may create uncertainty about when laboratories conducting BRCA testing in Europe infringe the IP.

Login | Subscribe